Seeing Is Believing
Currently out of the existing stock ratings of Esther Rajavelu, 48 are a BUY (76.19%), 8 are a SELL (12.7%), 7 are a HOLD (11.11%).
Analyst Esther Rajavelu, currently employed carries an average stock price target met ratio of 58.09% that have a potential upside of 31.44% achieved within 221 days. Previously, Esther Rajavelu worked at UBS.
Esther Rajavelu’s has documented 140 price targets and ratings displayed on 17 stocks. The coverage was on the Healthcare sector.
Most recent stock forecast was given on RGNX, Regenxbio at 17-Jan-2024.
Analyst best performing recommendations are on VNDA (VANDA PHARMACEUTICALS).
The best stock recommendation documented was for VNDA (VANDA PHARMACEUTICALS) at 2/14/2019. The price target of $21 was fulfilled within 1 day with a profit of $0.88 (4.37%) receiving and performance score of 43.74.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Time (Days) For PT To Be Met
Performance score
Buy
$400
$156.74 (64.43%)
$400
16 days ago
(04-Nov-2024)
1/20 (5%)
$128.75 (47.47%)
664
Buy
$300
$56.74 (23.32%)
$300
19 days ago
(01-Nov-2024)
20/21 (95.24%)
$26.09 (9.53%)
220
Buy
$320
$76.74 (31.55%)
$320
19 days ago
(01-Nov-2024)
12/15 (80%)
$46.09 (16.83%)
215
Buy
$329
$85.74 (35.25%)
$295
19 days ago
(01-Nov-2024)
17/18 (94.44%)
$55.09 (20.11%)
247
Buy
$384
$140.74 (57.86%)
$366
19 days ago
(01-Nov-2024)
5/9 (55.56%)
$110.09 (40.19%)
335
What Year was the first public recommendation made by Esther Rajavelu?